Objective: To investigate the comparative patient satisfaction with  Silodosin and Tamsulosin in men with lower urinary tract  symptoms (LUTS) and Benign Prostate Hyperplasia and also to evaluate the impact of counselling among patients

Patients and Methods: 30 patients were included in the study with 15 patients in each groups with Silodosin 8 mg once daily and Tamsulosin 0.4 mg once daily. Patients were interviewed during the first visit in the department, appropriate patient counselling was provided and were followed up in the next two visits. The patient satisfaction on treatment was assessed by using PPSM (Patient Perception of Study Medication) questionnaire and the impact of patient counseling on Quality of Life was assessed using IPSS Q8 (International Prostate Symptom Score) and BPH Impact Index (BII) at each visits.

Results: Both the therapies resulted in significant improvements in PPSM, BII and IPSS scores from baseline. Assessments using the PPSM questionnaire showed that both the drugs increase patient satisfaction significantly, but between group comparisons showed that a significantly higher proportion of patients were satisfied with Silodosin therapy than Tamsulosin therapy. IPSS scores improved more significantly in Silodosin group compared to Tamsulosin group showing more symptom relief in the former group than latter. There was significant improvement in BII scores and IPSS Q8 scores showing significant improvement in patients’ quality of life.

Conclusions: The present data from the pilot study show that therapy with Silodosin and Tamsulosin provides significantly greater improvements in patient-reported, disease-specific QoL and treatment satisfaction but Silodosin was found to be the drug with more patient satisfaction in men with BPH symptoms and prostate enlargement. Patient counselling on BPH had an impact on the health related quality of life on both the groups.

Keywords: BPH Impact Index (BII), PPSM, Silodosin, Tamsulosin, LUTS, I-PSS.

1. AUA Guidelines 2018. Harris E Footer, Michael J Barry et al. Available at www.auanet.org.
2. EAU guidelines on BPH. J J de la Rosette et al. available at European urology 40(3):256-263 oct 2001.
3. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338:557-563.
4. Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarrete R, Nordling J, Roehrborn C, Schulman C, Teillac P, Tubaro A, Nickel JC: Benign prostatic hyperplasia: A progressive disease of the ageing male. Urology 2003, 61:267-73.
5. Mandal s et al. International journal of basic clinical pharmacology, 2017 july;6 (7):1631-1637. Patient reported outcomes with medical management of bening prostate hyperplasia: aprospective study in a tertiary care teaching hospital of rural West Bengal, India.
6. Ikemoto I, Kiyota H , Suzuki Y , Oishi Y, Kishimoto K, Shimomura T et al. Roles of BPH impact indexin the evaluation of impaired urination in patients with BPH .The Japanese journal of urology .2005;96:623-31.
7. Libby Black, Alyson Grove, Betsy Morril.Psychometric validation of a US English satisfaction measure for patients with Benign prostate hyperplasia and lower urinary tract symptoms.Health andquality of life outcomes, 2009, 7:55.
8. Boyarsky S, Jones G, Paulson DF, Prout GR: New look at bladder neck obstruction by the Food and Drug Administration regulators. Trans Am Assoc Genitourin Surg 1976, 68:29-32.
9. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett ATK, the Measurement Committee of the American Urological Association: The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. J Urology 1992, 148:1549-1557.
10. Barry MJ, Fowler FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK: Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995, 33:AS145-AS155.
11. Weaver M, Patrick DL, Markson LE, Martin D, Frederic I, Berger M: Issues in the measurement of satisfaction and treatment. AmJ Manag Care 1997, 3:579-594.
12. Shikiar R, Rentz AM: Satisfaction with medication: An overview of conceptual, methodological, and regulatory issues. ValueHealth 2004, 7:204-215.
13. Pontari MA: Chronic prostatitis/chronic pelvic pain syndrome in elderly men: toward better understanding and treatment. Drugs Aging 2003, 20:1111-1125.
14. Collins MM, Stafford RS, O'Leary MP, Barry MJ: Distinguishing chronic prostatitis and benign prostatic hyperplasia symptoms: results of a national survey of physician visits. Urology 1999, 53:921-925.
15. Litwin MS, McNaughton-collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, Alexander RB, Farrar JT, O'Leary MP: The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. JUrol 1999, 162:369-375.
16. Francesco Montorsi, Giorgio Gandaglia, Christopher Chapple, Francisco Cruz, Francois Desgrandchamps and Carlos Llorente : Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study) : International Journal of Urology (2016) 23, 572—579
17. Jack Barkin, Claus G. Roehrborn, Paul Siami, Olivier Haillot, Betsy Morrill, Libby Black and Francesco Montorsi : Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the combat trial : B J U, Intenational (2009) 103, 919-926
18. Matthias Oelke, François Giuliano, Simin K. Baygani, Thomas Melby and Angelina Sontag : Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study : BJU Int 2014; 114: 568–575

Dr Babitha M

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.